Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

4.64USD
11 Dec 2017
Change (% chg)

$-0.41 (-8.12%)
Prev Close
$5.05
Open
$5.07
Day's High
$5.07
Day's Low
$4.57
Volume
83,129
Avg. Vol
45,149
52-wk High
$10.86
52-wk Low
$2.93

Latest Key Developments (Source: Significant Developments)

Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 6 Dec 2017 08:39am EST 

Dec 6 (Reuters) - PERCEPTIVE ADVISORS LLC :PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC <<>>AS OF NOV 6 - SEC FILING.  Full Article

Oncomed posts Q3 loss per share $0.28
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces third quarter 2017 financial results and operational highlights.Q3 loss per share $0.28.Q3 revenue $5.1 million versus $5.9 million.Oncomed Pharmaceuticals Inc - ‍anticipates 2017 full-year cash utilization will be approximately $90 million​.Oncomed says current cash balance sufficient to fund pipeline development & operations through Q3 2019, before considering potential opt-in milestones​.Oncomed Pharmaceuticals - ‍now plans to initiate Phase 1B portion of anti-tigit trial to study anti-tigit in combination with anti-PD1 in H1 2018​.  Full Article

OncoMed CEO Paul Hastings to take medical leave of absence
Tuesday, 19 Sep 2017 08:30am EDT 

Sept 19 (Reuters) - OncoMed Pharmaceuticals Inc -:OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence.OncoMed Pharmaceuticals Inc - ‍Hastings will continue to be chief executive officer and chairman of board of directors during his leave of absence​.OncoMed Pharmaceuticals Inc - ‍ in Hastings' absence, co will be led by company's senior management team including creation of an office of president​.  Full Article

OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial
Wednesday, 13 Sep 2017 08:05am EDT 

Sept 13 (Reuters) - OncoMed Pharmaceuticals Inc :OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial.  Full Article

Oncomed Pharmaceuticals Q2 loss per share $0.40
Wednesday, 2 Aug 2017 04:05pm EDT 

Aug 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces second quarter 2017 financial results.Q2 loss per share $0.40.Q2 revenue $6.2 million versus $6.7 million.  Full Article

Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial
Thursday, 4 May 2017 08:30am EDT 

May 4 (Reuters) - Oncomed Pharmaceuticals Inc : :Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial.Oncomed Pharmaceuticals Inc - trial will be conducted at five centers in U.S. And is expected to enroll approximately 30 patients..  Full Article

Oncomed reports workforce reduction
Monday, 24 Apr 2017 04:35pm EDT 

April 24 (Reuters) - Oncomed Pharmaceuticals Inc ::Oncomed announces workforce reduction.Oncomed Pharmaceuticals Inc - oncomed will reduce its workforce by approximately 50 percent, resulting in 64 remaining full-time employees.Oncomed Pharmaceuticals Inc - company anticipates having sufficient cash to fund operations through q3 2019.Oncomed Pharmaceuticals Inc - anticipates having sufficient cash to fund operations through q3 2019.Oncomed Pharmaceuticals - expects to realize significant cost savings of about $60 million over next 2 years associated with personnel, operating expenses.Oncomed Pharmaceuticals - estimates one-time severance related charges of $2.6 million related to termination benefits and other related expenses.Oncomed Pharmaceuticals Inc - adjusted guidance for its anticipated 2017 expenses to approximately $90 million.Oncomed Pharmaceuticals Inc - majority of severance-related charges will be paid by end of q2 of 2017.Oncomed Pharmaceuticals Inc - "will also seek to maximize value from potential interest in partnering assets to which it has worldwide rights".  Full Article

Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints
Monday, 17 Apr 2017 08:00am EDT 

April 17 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints.Oncomed Pharmaceuticals Inc - trial did not meet its primary endpoint of progression-free survival or secondary endpoints.Also announces discontinuation of brontictuzumab Phase 1B study.  Full Article

Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept
Monday, 10 Apr 2017 08:02am EDT 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept . Oncomed - Bayer Pharma notified co of decision not to exercise option to license WNT pathway inhibitors vantictumab, ipafricept for strategic reasons . Oncomed - Effective June 2017, co to retain worldwide development & commercialization rights to vantictumab, ipafricept, WNT pathway biologics . Oncomed Pharmaceuticals Inc - small molecule program under companies' collaboration continues without change .Oncomed - will be conducting internal portfolio review and prioritization to determine next steps for all programs, including vantictumab, ipafricept.  Full Article

OncoMed Phase 2 demcizumab pancreatic cancer trial misses primary endpoint
Monday, 10 Apr 2017 08:00am EDT 

OncoMed Pharmaceuticals Inc : OncoMed phase 2 demcizumab pancreatic cancer trial misses primary endpoint . OncoMed Pharmaceuticals Inc says trial did not meet primary endpoint of progression-free survival . OncoMed Pharma -interim median overall survival analysis did not show benefit for demcizumab in combination with abraxane plus gemcitabine versus abraxane . OncoMed Pharmaceuticals Inc says safety data seen in yosemite trial were generally consistent and in line with expectations . OncoMed Pharma -based on lack of benefit over standard-of-care, co will be discontinuing Yosemite clinical trial of demcizumab . OncoMed Pharma - will also discontinue any additional enrollment in other ongoing demcizumab trials, conduct analyses of data from those trials as planned .OncoMed Pharma - remains focused on completing, analyzing results of 2 randomized phase 2 clinical trials, pinnacle, denali, are anticipated in h1 of this year.  Full Article

BRIEF-Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals

* PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC AS OF NOV 6 - SEC FILING Source text: [http://bit.ly/2nzZrC0] Further company coverage: